Strong Quarterly Funds Performance
Funds were up approximately 11% in Q4 2025 including refining hedges and up approximately 9% excluding refining hedges; for the full year funds were flat including hedges and up ~7% excluding hedges. Top contributors in Q4 included EchoStar, refining hedges, and Sentry.
Sentry Rapid Growth and Deleveraging
Sentry reported base revenue and EBITDA growth of 25–28% (Q3 run-rate cited), and leverage declined to mid-2x EBITDA following an equity offering, providing significant financial flexibility.
Large AEP Capital Plan and Growth Outlook
AEP disclosed a $72 billion CapEx plan driving asset base growth at a 10% CAGR and expected EPS growth at a 9% CAGR through 2030, with potential incremental projects of $5–8 billion.
Improved Liquidity and Capital Position
Holding company had $3.5 billion in cash and investment in the funds at quarter-end; subsidiaries had $913 million in cash and revolver availability. Funds cash rose from approximately $750 million at year-end to more than $1.2 billion recently (an increase of over 60%).
Debt Reduction and Capital Actions
Management has reduced IEP corporate debt and called in the remaining balance of 2026 maturities; Board declared an unchanged distribution of $0.50 per depositary unit.
EchoStar Strategic Monetization
EchoStar sold additional spectrum to SpaceX in exchange for SpaceX common equity, demonstrating spectrum value and creating potential upside tied to a SpaceX IPO.
Operational Recovery Steps at CVI and Wynnewood
Management is focused on improving capture rates at CVI to boost profitability; in December CVI reverted the RDU at the Wynnewood refinery back to hydrocarbon processing (operational change intended to improve results).
Pharma Clinical Progress
TRANSCEND trial preparation for the PAH drug is on schedule with first patient expected to be dosed in 60–90 days; physician community is reportedly enthusiastic about potential disease‑modifying designation.